Savara Inc (SVRA) stock
SVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.48+0.02 (+0.34%)
Close on Nov 17, 2026Market cap $920.46MP/E –Yield –
Savara total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Savara's total debt was $30.11M at Jun 30, 2026. For fiscal 2025 it was $29.91M, up 12.4% from the year before. The highest annual figure on record is $29.91M in fiscal 2025.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.91M | +12.4% |
| FY2024 | Dec 31, 2024 | $26.62M | +1.0% |
| FY2023 | Dec 31, 2023 | $26.35M | +1.0% |
| FY2022 | Dec 31, 2022 | $26.08M | +1.6% |
| FY2021 | Dec 31, 2021 | $25.66M | +2.2% |
| FY2020 | Dec 31, 2020 | $25.10M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $30.11M | +1.5% |
| Q1 FY2026 | Mar 31, 2026 | $30.07M | +1.8% |
| Q4 FY2025 | Dec 31, 2025 | $29.91M | +12.4% |
| Q3 FY2025 | Sep 30, 2025 | $29.78M | +12.2% |
| Q2 FY2025 | Jun 30, 2025 | $29.65M | +12.0% |
| Q1 FY2025 | Mar 31, 2025 | $29.52M | +11.8% |
| Q4 FY2024 | Dec 31, 2024 | $26.62M | +1.0% |
| Q3 FY2024 | Sep 30, 2024 | $26.55M | +1.0% |
| Q2 FY2024 | Jun 30, 2024 | $26.48M | +1.0% |
| Q1 FY2024 | Mar 31, 2024 | $26.42M | +1.0% |
| Q4 FY2023 | Dec 31, 2023 | $26.35M | +1.0% |
| Q3 FY2023 | Sep 30, 2023 | $26.28M | +1.0% |
| Q2 FY2023 | Jun 30, 2023 | $26.21M | +1.0% |
| Q1 FY2023 | Mar 31, 2023 | $26.15M | +1.3% |
| Q4 FY2022 | Dec 31, 2022 | $26.08M | +1.6% |
| Q3 FY2022 | Sep 30, 2022 | $26.01M | +1.9% |
| Q2 FY2022 | Jun 30, 2022 | $25.94M | +2.2% |
| Q1 FY2022 | Mar 31, 2022 | $25.81M | +2.2% |
| Q4 FY2021 | Dec 31, 2021 | $25.66M | +2.2% |
| Q3 FY2021 | Sep 30, 2021 | $25.52M | – |
| Q2 FY2021 | Jun 30, 2021 | $25.38M | – |
| Q1 FY2021 | Mar 31, 2021 | $25.24M | – |
| Q4 FY2020 | Dec 31, 2020 | $25.10M | – |
See a number that looks wrong?